Ads
related to: winrevair fda approval date for evenity 10 percent
Search results
Results From The WOW.Com Content Network
Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. [6] It is an activin signaling inhibitor, [ 6 ] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). [ 9 ]
Winrevair, which costs around $238,000 annually, was the first treatment to secure approval from the U.S. Food and Drug Administration from a class of drugs, which target a type of protein called ...
The therapy, branded Winrevair, is approved for treating pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States. US FDA approves Merck's therapy for rare ...
Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [ 7 ] [ 8 ] It has been found to decrease the risk of fractures of the spine .
The company recently earned approval for Winrevair, a therapy for pulmonary arterial hypertension with a new mechanism of action. According to some analysts, Winrevair could hit sales of $3.9 ...
10 2014. 11 2013. 12 References. ... (FDA). Drugs may be listed more than once since breakthrough therapy can be awarded for multiple indications. ...
Ads
related to: winrevair fda approval date for evenity 10 percent